QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 20 February 2008
doi: 10.1242/dev.015370

This Article Summary Figures Only Full Text (PDF) All Versions of this Article: dev.015370v1 135/7/1271    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugimori, M. Articles by Nakafuku, M. Search for Related Content PubMed PubMed Citation Articles by Sugimori, M. Articles by Nakafuku, M.

Ascl1 is required for oligodendrocyte development in the spinal cord

¹ Division of Developmental Biology, Cincinnati Children's Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
² Biologie des Interactions Neurones/Glie, Unite Mixte de Recherche INSERM U-711, UPMC Hopital de la Salpetriere, 75651 Paris cedex 13, France.
³ Division of Molecular Neurobiology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK.
⁴ Departments of Pediatrics and Neurosurgery, University of Cincinnati College of Medicine, 125 Eden Avenue, Cincinnati, OH 45267, USA.
⁵ Solution Oriented Research for Science and Technology, Japan Science and Technology Agency, 3-4-15, Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan.

^* Author for correspondence (e-mail: masato.nakafuku{at}cchmc.org)

Accepted 17 January 2008

	SUMMARY

TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Development of oligodendrocytes, myelin-forming glia in the central nervous system (CNS), proceeds on a protracted schedule. Specification of oligodendrocyte progenitors (OLPs) begins early in development, whereas their terminal differentiation occurs at late embryonic and postnatal periods. How these distinct steps are controlled remains unclear. Our previous study demonstrated an important role of the helix-loop-helix (HLH) transcription factor Ascl1 in early generation of OLPs in the developing spinal cord. Here, we show that Ascl1 is also involved in terminal differentiation of oligodendrocytes late in development. Ascl1^-/- mutant mice showed a deficiency in differentiation of myelin-expressing oligodendrocytes at birth. In vitro culture studies demonstrate that the induction and maintenance of co-expression of Olig2 and Nkx2-2 in OLPs, and thyroid hormone-responsive induction of myelin proteins are impaired in Ascl1^-/- mutants. Gain-of-function studies further showed that Ascl1 collaborates with Olig2 and Nkx2-2 in promoting differentiation of OLPs into oligodendrocytes in vitro. Overexpression of Ascl1, Olig2 and Nkx2-2 alone stimulated the specification of OLPs, but the combinatorial action of Ascl1 and Olig2 or Nkx2-2 was required for further promoting their differentiation into oligodendrocytes. Thus, Ascl1 regulates multiple aspects of oligodendrocyte development in the spinal cord.

Key words: Cell fate, Oligodendrocyte, Myelin, Glia, Stem cell, Transcription factor, HLH factor, Spinal cord, Mouse

	INTRODUCTION

TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Oligodendrocytes are the major constituent of myelin in the vertebrate CNS, and play important roles in its formation and function (Raff, 1989). Although myelin is formed mostly in the postnatal period in mammals, specification of oligodendrocytes occurs relatively early during development (Noble et al., 2004; Richardson et al., 2006). Early cells in the oligodendrocyte lineage retain the capacity of cell divisions, and thus are called oligodendrocyte progenitors (OLPs) (Barres and Raff, 1994). OLPs are first specified from multipotent progenitors in the ventricular zone (VZ) located on the inner side of the developing neural tube. These specified OLPs subsequently migrate to the forming outer layer called the mantle zone (MZ) and spread throughout the CNS parenchyma (Richardson et al., 2006). These migratory OLPs remain undifferentiated until the perinatal period, and begin to undergo terminal differentiation and express myelin genes mostly in the postnatal period. Thus, oligodendrocyte development occurs on a protracted time course.

Recent studies have revealed that each of these steps occurs at distinct stages in different regions. For example, OLPs in the developing spinal cord had long been thought to arise from a restricted ventral progenitor domain (Rowitch, 2004; Richardson et al., 2006). It has recently been shown, however, that OLPs arise in multiple progenitor domains along the dorsoventral axis at distinct developmental stages (Spassky et al., 1998; Liu et al., 2003; Cai et al., 2005; Vallstedt et al., 2005; Fogarty et al., 2005; Sugimori et al., 2007). Recent studies have also demonstrated multiple origins of oligodendrocytes in the developing forebrain (Kessaris et al., 2006; Yue et al., 2006). In the spinal cord, these specified OLPs express either Nkx2-2 or Olig2, thereby comprising two molecularly distinct populations at early stages (Lu et al., 2002; Zhou and Anderson, 2002; Fu et al., 2002; Liu and Rao, 2004; Danesin et al., 2006; Sugimori et al., 2007). The terminal differentiation of these OLPs also occurs at specific stages in distinct regions. In the rodent spinal cord, myelin gene expression is initiated in the dorsal and ventral regions near the midline around birth (Fu et al., 2002; Wang et al., 2006). Subsequently, it spreads laterally along the forming white matter, and then gradually proceeds in the inner gray matter postnatally. Thus, both specification and terminal differentiation of oligodendrocytes are under precise spatiotemporal control.

Previous studies have demonstrated that multiple classes of transcription factors are involved in this process. They include the HLH factors Olig1 and Olig2 (Lu et al., 2002; Zhou and Anderson, 2002; Takebayashi et al., 2002), Ascl1 (Kondo and Raff, 2000a; Wang et al., 2001; Parras et al., 2004; Parras et al., 2007; Gokhan et al., 2005; Sugimori et al., 2007), and Id2, Id4 and Hes5 (Kondo and Raff, 2000b; Wang et al., 2001; Samanta and Kessler, 2004; Liu et al., 2006), the homeodomain factors Nkx2-2 and Dlx1/2 (Qi et al., 2001; Fu et al., 2002; Liu et al., 2007; Petryniak et al., 2007), zinc-finger factor Zfp488 (Wang et al., 2006), and multiple members of the Sox family (Stolt et al., 2002; Stolt et al., 2003; Stolt et al., 2004; Stolt et al., 2006; Sohn et al., 2006). How these molecules control the timing of oligodendrocyte development, however, is not yet fully understood. Our recent studies have shown that Ascl1 controls specification of OLPs at an early embryonic stage in the spinal cord and forebrain (Sugimori et al., 2007; Parras et al., 2007). Interestingly, recent studies have shown that Ascl1 is also expressed in postnatal and adult OLPs (Parras et al., 2007; Aguirre et al., 2007; Kim et al., 2007). Its in vivo role in oligodendrocyte development, however, remains unclear. Here, we show that Ascl1 plays an important role in differentiation of OLPs into myelin-expressing oligodendrocytes at late embryonic stages in the spinal cord.

	MATERIALS AND METHODS

TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Animals
All animal procedures were performed according to the guidelines and regulations of the Institutional Animal Care and Use Committee and the National Institute of Health. The maintenance and genotyping of Ascl1^-/- (Parras et al., 2002) and Ascl1::GFP mice (Gong et al., 2003) were described previously (Parras et al., 2007). Embryos and pups of the wild-type and mutant mice and Sprague-Dawley rats were collected from timed-pregnant females.

Immunostaining
Rabbit anti-Nkx2-2 and guinea pig anti-Olig2 antibodies were kind gifts from Dr T. Jessell at Columbia University. Mouse monoclonal antibody for Nkx2-2 was obtained from the Developmental Studies Hybridoma Bank at the Iowa University. Rabbit antibodies for Ascl1, Olig1, Olig2 and Pax6 have been described previously (Mizuguchi et al., 2001). Antibodies for following antigens were purchased from commercial sources: Ascl1, platelet-derived growth factor receptor (PDGFR) and activated caspase 3 (BD Bioscience); O4, galactocerebroside (GalC), NG2 (chondroitin sulfate proteoglycan 4, Cspg4), myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) (Millipore); 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP; CNP1) and glial fibrillary acidic protein (GFAP) (Sigma-Aldrich); β-tubulin type III (TuJ1) (Babco); Sox10 (Santa Cruz); and green fluorescent protein (GFP) (Invitrogen). Labeling of dividing cells with 5-bromo-2'-deoxyuridine (BrdU) was performed by administering BrdU (50 mg/kg) to pregnant animals 2 hours before sampling of embryos. Staining was visualized with secondary antibodies conjugated with Alexa Fluor 488, 555, 568, 594 and 633 (Invitrogen), and images were obtained using Zeiss LSM-510 confocal microscope or Apotome as described previously (Sugimori et al., 2007; Parras et al., 2007).

Reverse transcriptase polymerase chain reaction (RT-PCR) and in situ hybridization
The expression of Ascl3 and Ascl5 in the developing spinal cord was examined by RT-PCR and in situ hybridization. The following primers were used to obtain cDNAs encoding the predicted full-length open reading frames of Ascl3 and Ascl5 (sequences corresponding to the initiation and termination codons are underlined): Ascl3, 5'-GAAACGATGGACACCAGAAGC-3' and 5'-CTGATTCAAATGACTCTCAGAG-3'; and Ascl5, 5'-CATTATGAACAGTAACT-3' and 5'-GCCAGATCAAAGGCTGGGTT-3'. cDNAs reverse transcribed from total RNAs isolated from embryonic (E)10.5 and E16.5 mouse spinal cords were used as templates. The identity of PCR products was verified by sequencing. These cDNAs were used for in situ hybridization as described previously (Mizuguchi et al., 2001).

Cell culture
Neurosphere culture and infection of recombinant retroviruses were performed as described previously (Sugimori et al., 2007). The titer of viruses was adjusted to infect 70% of total cells in culture. In double infection experiments, conditions were established for each combination of two different viruses to ensure that more than 85% of GFP⁺ cells co-expressed two transgenes simultaneously. The expression level of transgene products in infected cells was examined by analyzing digital images captured by CCD camera (Hamamatsu Photonics C5810) using Image J software.

To examine the time course of differentiation of OLPs, spinal cords between the upper and lower limb levels were collected from embryos and pups between E14.5 and postnatal (P) 0. Isolated tissue stumps were dissociated and subjected to immunostaining as described previously (Ohori et al., 2006). Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (100 µg/ml; Sigma-Aldrich).

To examine differentiation of oligodendrocytes in vitro, spinal cord cells collected from Ascl1^-/- embryos and their wild-type littermates at E16.5 and E18.5 were seeded at a density of 2x10⁴ cells/ml and cultured for 7 or 14 days. In some cases, thyroid hormone (TH) (triiodothyronine, 30 ng/ml; Sigma-Aldrich) was added to the culture. To expand OLPs in culture, the cells were first grown for 7 days in the presence of fibroblast growth factor 2 and epidermal growth factor (20 ng/ml for each, Peprotech), and subsequently maintained for additional 4 days without growth factors.

	RESULTS

TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Expression of Ascl1 in OLPs at late embryonic stages
Our previous study has shown that Ascl1 expression in OLPs occurs transiently at the time when they are specified in the VZ (Sugimori et al., 2007). Its expression pattern at later stages, however, has not yet been examined in details. Thus, we first followed the developmental time course of Ascl1 expression in the rat spinal cord.

At E14.5, Olig2⁺ and Nkx2-2⁺ cells scattered in the spinal cord did not express Ascl1 at a detectable level, except for those in and adjacent to the VZ (see Sugimori et al., 2007). The majority of them were positive for O4 and PDGFR, and thus considered to be OLPs (Fu et al., 2002; Liu and Rao, 2004; Danesin et al., 2006; Sugimori et al., 2007). From E16.5 onwards, however, Olig2⁺ and Nkx2-2⁺ cells beneath the pial surface began to express Ascl1. In particular, the majority of Olig2⁺ (95%, 112/118 cells examined) and Nkx2-2⁺ (58%, 88/153) cells were Ascl1⁺ near the dorsal and ventral midline areas and the lateral margin of the MZ (Fig. 1A, boxed areas and inset, Fig. 1B,C). In the same areas, 68% (131/194) of Olig2⁺ cells expressed Nkx2-2, and, conversely, 92% (131/142) of Nkx2-2⁺ cells were Olig2⁺ (Fig. 1D).

At E18.5, the frequency of co-expression of Ascl1, Olig2 and Nkx2-2 increased in both inner and outer parts of the MZ (Fig. 1E-H). Yet, OLPs that just began to leave the VZ at this late stage did not co-express Olig2 and Nkx2-2, and remained negative for Ascl1 (Fig. 1I, and data not shown). At E20.5 and P0, however, the majority of OLPs appeared to co-express these transcription factors throughout the MZ (Fig. 2A-D,I,J). Following their co-expression, the first population of GalC⁺ and MBP⁺ oligodendrocytes emerged at E20.5 (Fig. 2E-H) and increased in number at P0 (Fig. 2M-O) beneath the pial surface. These myelin-expressing cells expressed Ascl1 and Olig2 (Fig. 2E-H,K-O).

To further examine the relationship between Ascl1 expression and OLP development, we used Ascl1::GFP mice in which GFP expression is driven by the Ascl1 locus on a transgene (Gong et al., 2003). In this reporter line, GFP protein sustains longer than endogenous Ascl1 so that progeny of Ascl1⁺ progenitors can be transiently marked as GFP⁺ cells (Parras et al., 2007). In fact, more GFP⁺ cells than Ascl1⁺ cells were detected in Ascl1::GFP mice at E16.5, the stage when both neurons and OLPs are generated (Fig. 3A-A'') (Helms et al., 2005; Mizuguchi et al., 2006; Sugimori et al., 2007). Many of these GFP⁺ cells, especially those in the dorsal MZ, were negative for PDGFR, a marker for migrating OLPs (Fig. 3A-A''). Likewise, GFP expression overlapped with PDGFR and Ascl1 in some, but not all cells in the VZ (Fig. 3B-B'',E,F-F''). These GFP⁺/PDGFR^- cells are likely to be neurons and neuronal progenitors. Importantly, many PDGFR⁺ cells in the MZ expressed GFP (Fig. 3B-D''). The vast majority of PDGFR⁺ cells were GFP⁺ in the ventral half of the MZ (Fig. 3D-D'', arrowheads), whereas a significant fraction of PDGFR⁺ cells were negative for GFP in the dorsal MZ (Fig. 3C-C'', arrows). These dorsal GFP^-/PDGFR⁺ cells might have derived from Ascl1^- progenitors or downregulated GFP during migration. Nevertheless, most of the PDGFR⁺ cells detected near the pial surface were GFP⁺ in both the ventral and dorsal aspects of the spinal cord, and some of them expressed endogenous Ascl1 (Fig. 3G-H''). These results demonstrate that Ascl1 expression occurs in a significant fraction of OLPs late in development.

View larger version (94K): [in this window] [in a new window]   Fig. 1. Expression of Ascl1 at late embryonic stages. Transverse sections of rat spinal cord at the brachial level at E16.5 (A-D) and E18.5 (E-I). Molecules stained in red and green are shown at the top. Broken lines indicate the boundary between the VZ and MZ or the forming white matter of the spinal cord. Boxes in A and E show the locations of the areas shown in other panels. Insets show double-labeled cells in the dorsomedial white matter (unlabelled boxed areas in A,E) or the ventral white matter (B-D,F). Arrowheads indicate double-labeled cells, whereas arrows in I indicate separate Olig2+ and Nkx2-2+ cells. FP, floor plate; MZ, mantle zone; VZ, ventricular zone. Scale bars: 200 µm in A,E; in D,H and I, 50 µm for B-D,F-H and I.

View larger version (77K): [in this window] [in a new window]   Fig. 2. Co-expression of Ascl1, Olig2 and Nkx2-2 in differentiating OLPs at perinatal stages. Images show staining of rat spinal cord for Ascl1, Olig2 and Nkx2-2, together with GalC and MBP at E20.5 (A-H) and P0 (I-O). Boxes in E and M indicate the locations of the areas shown in other panels. D shows a triple-positive cell (merged image on the left). Insets and arrowheads indicate double-positive cells. Asterisks in I indicate Olig2+/Ascl1- cells. Broken lines indicate the boundary between the VZ and MZ. Scale bars: in C,G and L, 50 µm for A-C, F,G and I-L; 100 µm in E,H,N,O; 200 µm in M.

At P0, a significant fraction of Olig2⁺ cells became negative for Ascl1 and Nkx2-2 (Fig. 2I, asterisks; Fig. 4D). These cells could become astrocytes at postnatal stages (Masahira et al., 2006; Cai et al., 2007) or remain as undifferentiated OLPs up to adulthood (Yamamoto et al., 2001; Kitada and Rowitch, 2006; Ohori et al., 2006). Moreover, many MBP⁺ cells became negative for Ascl1 at this stage (Fig. 4D). This could be because Ascl1 expression in myelin⁺ cells is transient or, alternatively, because a separate population of oligodendrocytes emerges from Ascl1-negative OLPs postnatally. In summary, these results demonstrate a temporal correlation between the co-expression of Ascl1 with Olig2 and Nkx2-2, and terminal differentiation of oligodendrocytes.

View larger version (138K): [in this window] [in a new window]   Fig. 3. Expression of Ascl1-GFP transgene in PDGFR+ OLPs. Images show transverse sections of E16.5 spinal cords of Ascl1::GFP reporter mice. (A-D'') Ascl1-GFP and PDGFR were stained in green and red, respectively, and cell nuclei were stained with DAPI in blue. (E-H'') Co-staining for Ascl1-GFP (green), PDGFR (blue) and endogenous Ascl1 protein (red). Boxes indicate the locations of the areas shown in other panels. Broken lines in B-B'' indicates the VZ. Arrowheads indicate the co-expression of GFP and PDGFR, whereas arrows indicate GFP-/PDGFR+ (C-C'') or Ascl1-/GFP+/PDGFR+ cells (F-F'',H-H''). Scale bars: 50 µm in A-A''; in B'',C'',D'',E,G,F'' and H'', 20 µm for B-B'',C-C'',D-D'',E,F-F'' and H-H''.

To follow the recovery of OLPs in Ascl1^-/- mutants, we examined earlier stages. In our previous study (Sugimori et al., 2007), we detected a significant reduction (60-90%) in the number of OLPs in both the VZ and MZ at E12.5 and E14.5, the stages when early OLPs are generated in the ventral spinal cord. Consistent with this, the number of NG2⁺ OLPs in the MZ remained smaller in Ascl1^-/- embryos compared with the wild type at E14.5 (49.2±12.3%, n=3) and E16.5 (57.7±8.5%). This mutant phenotype is likely to be attributable to a specification defect, but attenuated proliferation of specified OLPs could also underlie the observed reduction. However, their number in and adjacent to the VZ, which were thought to reflect OLPs newly generated at these late stages, was comparable (15±2 and 17±3 NG2⁺ cells per section in the wild type and mutant, respectively, at E14.5, and 17±2 and 18±4 cells at E16.5, n=4-6 sections at the brachial level per embryos and three embryos examined). A similar recovery was observed for Olig1⁺ and Nkx2-2⁺ cells (data not shown). These cells were detected not only in the ventral but also in the dorsal VZ as has been shown in previous studies (Cai et al., 2005; Vallstedt et al., 2005; Fogarty et al., 2005; Sugimori et al., 2007) (data not shown). Thus, OLP generation was defective only at early stages when they were preferentially produced in the ventral spinal cord. The number of OLPs recovered at later stages in Ascl1 mutants, probably because of continuous production of OLPs in multiple progenitor domains over a prolonged period late in development.

The above results suggest that molecules other than Ascl1 promote OLP specification Ascl1^-/- mice. We hypothesized that HLH factors related to Ascl1 exert such a function. In fact, we found that two Ascl1-related genes, Ascl3 and Ascl5 (Mouse Genome Informatics: http://www.informatics.jax.org/) are expressed in the developing spinal cord at both E10.5 and E16.5 (Fig. 5A). At E10.5, the expression of Ascl3 and Ascl5 mRNAs was detected in both the dorsal and ventral aspects of the VZ, but excluded from the Olig2⁺ motoneuron progenitor domain (pMN), similarly to Ascl1 (Fig. 5B-D). We also examined the activity of Ascl3 and Ascl5 in vitro. Our previous study has shown that Ascl1 promotes both neurogenesis and oligodendrogenesis in E13.5 spinal cord-derived multipotent progenitors (Sugimori et al., 2007). Under the same conditions, retrovirus-mediated overexpression of Ascl3 and Ascl5 also promoted differentiation of TuJ1⁺ neurons and O4⁺ oligodendrocytes at the expense of GFAP⁺ astrocytes (Fig. 5E-G). These results suggest that Ascl3 and Ascl5 are involved in oligodendrogenesis in Ascl1^-/- spinal cords. Their in vivo function, however, awaits further studies.

View larger version (41K): [in this window] [in a new window]   Fig. 4. Temporal sequence of the co-expression of Ascl1, Olig2 and Nkx2-2. (A,B) Stage-dependent increase in the number of Ascl1+, Olig2+ and Nkx2-2+ cells (A), and NG2+, GalC+ and MBP+ (B) cells. Cells isolated from rat spinal cords between the upper and lower limbs were subjected to immunostaining. Data are mean±s.d. obtained from three independent experiments. The number of cells triple positive for Ascl1, Olig2 and Nkx2-2 was estimated based on the results of a series of double staining. (C) Immunostaining of dissociated spinal cord cells for various markers at E20.5. Arrowheads indicate cells double positive for respective markers. (D) Developmental changes in the co-expression pattern of various markers. The percentages of cells positive for a given marker (leftmost column) that were double positive for other markers (top column) are shown. Data are the mean of three independent experiments. Scale bars: in C, parts c,f, 20 µm for C, parts a-f; in C, part i, 50 µm for C, parts g-i.

Ascl1^-/- mice die at birth, and therefore differentiation of Ascl1^-/- OLPs was examined in vitro. Cells isolated from E18.5 spinal cords were cultured in the presence and absence of thyroid hormone (TH) to stimulate oligodendrocyte differentiation (Kondo and Raff, 2000a). When NG2⁺ OLPs undergo terminal differentiation, they first become NG2⁺/GalC⁺ intermediate cells, and subsequently differentiate into NG2^-/GalC⁺ and MBP⁺ oligodendrocytes. In the wild-type culture, a significant fraction of cells was GalC⁺ at day 1 after plating (DAP1) (5.9±1.5% of total cells, n=3), and about a half of them (49±13%) had already proceeded to the NG2^-/GalC⁺ state (Fig. 6J). In the mutant culture, however, GalC⁺ cells were smaller in percentage, and the majority of them (89±11%) remained as NG2⁺/GalC^- cells (Fig. 6K). Likewise, 3.6±0.8% (n=3) of wild-type cells already expressed MBP at DAP1, and their percentage significantly increased at DAP7 (Fig. 6L,N). MBP⁺ cells were further increased about twofold (2.4±0.5-fold) by treatment with TH (Fig. 6N). By contrast, few cells were MBP⁺ in the mutant culture at DAP1, and a much lower percentage of cells were MBP⁺ cells at DAP7 (Fig. 6M,N). Their percentage remained lower in the mutant culture (4.3±0.8%) than in the wild type (14.5±2.9%) at DAP14. Moreover, TH-dependent increase of MBP⁺ cells in the mutant culture (1.4±0.3-fold compared with untreated culture) was significantly smaller than that in the wild-type culture (P<0.05, n=3), suggesting a poor responsiveness of mutant cells to TH. Cells from heterozygous mice (Ascl1^+/-) did not show such a defect (data not shown). During the course of culture, the percentage of Olig2⁺ cells among total cells did not significantly differ between the wild-type and mutant cells (16.7±4.5% for the wild type and 15.8±2.9% for the mutant at DAP7). Thus, a loss of OLPs during culture is unlikely to account for the differentiation defect of mutant cells. These results suggest that the severe loss of myelin protein-expressing cells in the mutant is attributable to attenuated or delayed differentiation of OLPs.

View larger version (50K): [in this window] [in a new window]   Fig. 5. Expression and activity of Ascl3 and Ascl5. (A) Expression of Aslc3 and Ascl5 in the spinal cord at E10.5 and E16.5. mRNA expression was detected by RT-PCR using reverse-transcribed (RT+) and non-transcribed (RT-) RNA samples as templates. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) was used as internal control. (B-D) Expression of Ascl1 protein, and of Ascl3 and Ascl5 mRNA in the VZ of the mouse spinal cord at E10.5. The neural tube is outlined in C,D. Brackets indicate the position of the Olig2+ motoneuron progenitor domain (pMN). The horizontal lines indicate the boundary of the dorsal and ventral aspects of the VZ. (E-G) Neurogenic and oligodendrogenic activity of Ascl3 and Ascl5. Neurospheres derived from E13.5 spinal cords were infected with GFP retroviruses expressing Ascl1, Ascl3 and Ascl5, and subsequently induced to differentiate for 4 (E) or 10 (F,G) days. The percentages of GFP+ cells that differentiated into TuJ1+ neurons, O4+ oligodendrocytes and GFAP+ astrocytes were quantified (mean±s.d., three independent experiments). *P<0.01 compared with control virus-infected culture. Scale bar: 100 µm.

We also asked whether Ascl1 is involved in the maintenance of co-expression of Olig2 and Nkx2-2. The vast majority of Olig2⁺ cells isolated from E18.5 embryos co-expressed Nkx2-2 (Fig. 7C). Moreover, 84.6±8.6% of wild-type Olig2⁺ cells were Ascl1⁺ at this stage. The high percentage of co-expression Nkx2-2 in Olig2⁺ cells was maintained for 7 days in the wild-type culture, whereas only about a half of Ascl1^-/- Olig2⁺ cells remained Nkx2-2⁺. However, most Nkx2-2⁺ cells remained Olig2⁺ (>90%) at both DAP1 and DAP7, and the number of Olig2⁺ cells did not significantly differ between the wild-type and mutant cultures (data not shown). Thus, mutant Olig2⁺ OLPs were defective in maintaining the expression of Nkx2-2. These results demonstrate that one of the actions of Ascl1 in late-stage OLPs is to properly induce and maintain the co-expression of Olig2 and Nkx2-2.

Collaborative actions of Ascl1, Olig2 and Nkx2-2
We next performed gain-of-function studies using neurosphere culture. Multipotent progenitors from E13.5 spinal cords were infected with GFP retroviruses that expressed Olig2, Nkx2-2 and Ascl1 either alone or in combination. Although the expression level of endogenous and exogenous factors varied in individual cells, virus-mediated expression conferred about the same or a two-fold higher level of respective transcription factors compared with endogenous proteins (Fig. 8A-D). In neurosphere culture, specified OLPs were first detected as NG2⁺ cells, and they subsequently differentiated into GalC⁺ oligodendrocytes (Fig. 8E,F). We first compared the percentages of NG2⁺ and GalC⁺ cells among virus-infected cells (Fig. 8G,H). Consistent with previous reports (Zhou et al., 2001; Sun et al., 2001; Liu et al., 2007), both Olig2 and Nkx2-2 increased the fraction oligodendrocyte lineage cells among total cells. Olig2 increased both NG2⁺ OLPs and GalC⁺ oligodendrocytes, whereas Nkx2-2 increased NG2⁺ but not GalC⁺ cells. Like Olig2, Ascl1 increased both NG2⁺ and GalC⁺ cells. Thus, each of these transcription factors retained the ability to promote OLP specification. These effects were not observed in GFP^- cells within the same culture (data not shown), indicating their cell-autonomous actions. The rate of cell death did not significantly differ between cultures infected with different viruses, indicating that elimination of cells with specific phenotypes is unlikely to account for the observed effects.

View larger version (59K): [in this window] [in a new window]   Fig. 6. Defect in oligodendrocyte differentiation in Ascl1-/- spinal cords. (A-H) Co-immunostaining of CNP, MAG and MBP with Olig2 in wild type (A-D) and Ascl1-/- mutants (E-H). Boxed areas in A and E indicate the regions shown in other panels. Arrowheads indicate double-positive cells. Asterisks indicate non-specific staining outside the spinal cord. (I) Reduction of myelin+ oligodendrocytes in Ascl1-/- mutants at P0. Data are mean±s.d. obtained from staining of five or six sections derived from three embryos for each genotype. The percentage of the mutant level compared with the wild type is shown for each marker. *P<0.01. (J-M) Expression of GalC and NG2 (J,K) and MBP (L,M) in culture of wild-type and Ascl1-/- embryos. Cells from E18.5 spinal cords were cultured for 7 days. In J and K, arrows indicate NG2-/GalC+ oligodendrocytes, whereas arrowheads indicate NG2+/GalC+ intermediate cells. In L and M, arrows indicate MBP+ oligodendrocytes. Cell nuclei were stained with DAPI (blue). (N) Differentiation of MBP+ oligodendrocytes in vitro. Culture of E18.5 spinal cords was performed either the presence (+) or absence (-) of TH, and the percentage of MBP+ cells among total cells was quantified at DAP1 and DAP7 (mean±s.d., three independent experiments). Parentheses show the percentages of the mutant level compared with the wild type. *P<0.05, **P<0.01 compared with the wild type. Scale bars: in A,E, 200 µm; in D,H, 50 µm for B-D,F-H; in M, 50 µm for J-M.

View larger version (42K): [in this window] [in a new window]   Fig. 7. Defect in the co-expression of Olig2 and Nkx2-2 in Ascl1-/- spinal cords. (A) Co-expression of Olig2 and Nkx2-2 in vivo at E16.5. Arrowheads indicate Nkx2-2+/Olig2+ cells in the ventral white matter. Scale bar: 50 µm. (B,C) Expression of Nkx2-2 in Olig2+ OLPs in vitro. Spinal cord cells were isolated from either E16.5 (B) or E18.5 (C) embryos, and the expression of Nkx2-2 in Olig2+ cells was compared between the wild type and Ascl1-/- mutants at indicated time points. Data are mean±s.d. (n=3). *P<0.01 compared with DAP7; %P<0.01 compared with the wild type.

View larger version (55K): [in this window] [in a new window]   Fig. 8. Promotion of oligodendrocyte development by Ascl1. Neurospheres derived from E13.5 spinal cords were infected with GFP retroviruses expressing various transcription factors either alone or in combination, and subsequently induced to differentiate for 10 days. (A-D) Overexpression of Olig2, Nkx2-2 and Ascl1 in virus-infected cells. Cells infected with control (A), Olig2 (B), Nkx2-2 (C) and Ascl1 (D) viruses were stained for respective transcription factors together with GFP (both in green; see lower panels) and oligodendrocyte markers (red). Arrows indicate transgene expression in nuclei of cells with GFP+ soma, whereas arrowheads indicate the expression of endogenous factors in uninfected cells with GFP- soma. (E,F) Differentiation of virus-infected cells into NG2+ and GalC+ cells. The images show Ascl1 virus-infected cells expressing NG2 and GalC (arrowheads). Scale bars: in D and F, 20 µm for A-D and E,F. (G,H) Percentages of NG2+ and GalC+ cells among virus-infected cells (mean±s.d. from three or four independent experiments). Parentheses indicate the fold changes compared with the control level. *P<0.01 compared with the control virus; %P<0.01 compared with single infections.

View larger version (25K): [in this window] [in a new window]   Fig. 9. Combinatorial actions of Ascl1, Olig2 and Nkx2-2 in oligodendrocyte differentiation. (A-C) The percentages of cells with three distinct phenotypes among total virus-infected cells (mean±s.d. from three or four independent experiments). Viruses used for infection are shown on the left. (D) Promotion of oligodendrocyte differentiation by the combinatorial actions of Ascl1, Olig2 and Nkx2-2. The percentages of NG2+/GalC- (pale colors on the left), NG2+/GalC+ (middle) and NG2-/GalC+ (dark colors on the right) in the total oligodendrocyte lineage cells are compared between cultures infected with various viruses. *P<0.01 compared with the control virus; %P<0.01 compared with culture infected with Olig2 and Nkx2-2 viruses. $P<0.01 compared with culture infected with Ascl1 virus.

View larger version (18K): [in this window] [in a new window]   Fig. 10. Proposed actions of Ascl1 in oligodendrocyte development. In this model, Ascl1 regulates oligodendrocyte development at multiple steps (thick vertical arrows). At early stages, Ascl1 promotes specification of OLPs from multipotent progenitors (MP). At late embryonic and perinatal periods, Ascl1 regulates the co-expression of Olig2 and Nkx2-2, and subsequently cooperates with them to promote differentiation of myelin+ oligodendrocytes.

	DISCUSSION

TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

It is noteworthy that Ascl1 expression is biphasic during the course of oligodendrocyte development. This is in sharp contrast with the sustained expression of other transcription factors involved in oligodendrogenesis. For example, the expression of Olig2, Nkx2-2, Sox5 and Sox9 begins early in multipotent progenitors and continues in OLPs during late embryogenesis (Qi et al., 2001; Lu et al., 2002; Takebayashi et al., 2002; Stolt et al., 2003; Stolt et al., 2006). Olig1, Sox8 and Sox10 are induced in specified OLPs and maintained in mature oligodendrocytes (Lu et al., 2002; Zhou and Anderson, 2002; Takebayashi et al., 2002; Stolt et al., 2002; Stolt et al., 2004). By contrast, Ascl1 expression is transient at the time of OLP specification, and, once specified, OLPs remain negative for Ascl1 until the onset of their terminal differentiation.

How does Ascl1 control late-stage oligodendrocyte differentiation? Given that the co-expression of Olig2 and Nkx2-2 is impaired in Ascl1^-/- mutants, the severe reduction of myelin-expressing oligodendrocytes at birth could be attributable, at least in part, to this defect. In fact, the reported phenotypes of Nkx2-2^-/- mice are reminiscent of those observed in Ascl1^-/- mutants (Qi et al., 2001). However, our preliminary study suggests that the expression of Olig2 or Nkx2-2 is not under direct transcriptional control by Ascl1 (S.M. and M.N., unpublished). Our data also suggest that Ascl1 has a role other than their co-expression. Combinatorial overexpression of Olig2 and Nkx2-2 was not sufficient to promote the transition from OLPs to oligodendrocytes, whereas the combination of Ascl1 with Olig2 or Nkx2-2 strongly stimulated this maturation step. Moreover, differentiation of MBP⁺ cells was poorly stimulated by TH in culture of Ascl1^-/- cells, suggesting that Ascl1 is involved in regulating the responsiveness to TH. Interestingly, a previous study has shown that Ascl1 upregulates expression of the TH receptor TRβ1 in cultured OLPs (Kondo and Raff, 2000a). These results support the idea that Ascl1 regulates late-stage differentiation of oligodendrocytes at two steps: the co-expression of Olig2 and Nkx2-2, and the subsequent TH-responsive myelin gene expression (Fig. 10).

Cooperation of Ascl1 with Olig2 and Nkx2-2 in oligodendrocyte development
Ascl1 cooperated with Olig2 and Nkx2-2 to promote differentiation of OLPs into oligodendrocytes. It remains unknown at present what mechanisms underlie their collaborative actions. These transcription factors could cooperatively regulate the same set of downstream genes or, alternatively, control independent sets of genes that, in turn, mediate their collaborative actions. Given that combinatorial overexpression of these transcription factors was required for differentiation of OLPs, their overall expression levels and/or rations could be an important determinant for terminal differentiation of oligodendrocytes. Previous studies have shown that various inhibitory HLH factors negatively regulate myelin gene expression (Gokhan et al., 2005; Liu et al., 2006). Thus, it could be that the expression of Ascl1, Olig2 and Nkx2-2 needs to reach a certain level to counteract these inhibitors. Moreover, given that they act in both specification and differentiation of oligodendrocytes, additional molecules are likely to cooperate with them at each of these steps. A possible candidate is the Sox family of transcription factors. The reported defects in Sox9^-/-, Sox10^-/- and their double mutants are reminiscent of those in Ascl1^-/- mice (Stolt et al., 2003; Liu et al., 2007). Sox10 and Ascl1 have been shown to synergize to activate transcription of a MBP enhancer-driven reporter in vitro (Gokhan et al., 2005; Liu et al., 2006).

Ascl1-dependent and -independent oligodendrocyte development
Generation of OLPs at early stages is severely impaired in the Ascl1^-/- mutant spinal cord (Sugimori et al., 2007). This could be attributable to a defect in either specification or proliferation of early OLPs. The number of Olig2⁺ and Nkx2-2⁺ OLPs, however, recovered to the wild-type level around the perinatal stage. These cells expressed PDGFRa, Sox10 and NG2, suggesting that they retained the characteristics of OLPs. Thus, the differentiation defect of Ascl1^-/- OLPs at late stages appears not to be a mere consequence of their early specification defect. It remains possible, however, that mutant OLPs are defective in a manner that is not discernible using commonly used OLP markers, at the time of their specification, and that such an early defect is responsible for impaired differentiation at later stages.

Several lines of evidence support the idea that Ascl1 is required cell-autonomously in oligodendrocytes. Recent studies have provided genetic evidence for the expression of Ascl1 in the oligodendrocyte lineage (Battiste et al., 2007; Parras et al., 2007; Kim et al., 2007). Moreover, overexpression of Ascl1 stimulated differentiation of oligodendrocytes in a cell-autonomous manner in vitro. Our previous study has also shown that Ascl1^-/- mutant cells poorly differentiate into oligodendrocytes when grafted into the wild-type mice (Parras et al., 2004). These results, however, do not exclude the possibility that Ascl1 also regulates oligodendrogenesis in a non-cell-autonomous manner, i.e. through the regulation of other cell lineages.

It should also be noted that the defect in oligodendrocyte differentiation late in development was not complete in Ascl1^-/- mutants. It remains unknown whether this is simply due to delayed differentiation of all OLPs or to the inability of a subpopulation of OLPs to differentiate. Our previous studies have shown a partial or transient defect in OLP specification in the mutant brain (Parras et al., 2007). Wang et al. (Wang et al., 2001) reported that OLPs isolated from postnatal optic nerves of Ascl1^-/- mice show no noticeable defect in vitro. Thus, it is likely that there are Ascl1-dependent and -independent oligodendrocytes. The latter could originate from Ascl1 non-expressing cells or, alternatively, they could derive from Ascl1-expressing cells by Ascl1-independent mechanisms. We found that the Ascl1-related factors Ascl3 and Ascl5 are expressed in the developing spinal cord, and that like Ascl1, they are capable of promoting oligodendrogenesis in vitro. The redundant function of these Ascl factors may explain partial defects in both neurogenesis and oligodendrogenesis in many areas of the developing CNS in Ascl1^-/- mutants (Parras et al., 2002; Casarosa et al., 1999; Torii et al., 1999; Helms et al., 2005; Mizuguchi et al., 2006; Sugimori et al., 2007; Parras et al., 2007). Further understanding of the roles of Ascl1 and related HLH factors in oligodendrocytes should provide better insights into the mechanisms underlying development of this important glial cell type in the vertebrate CNS.

	ACKNOWLEDGMENTS

 
We are grateful to T. M. Jessell, T. Kitamura and I. Dobashi for reagents, and to K. Campbell for critical reading of the manuscript. This work was supported in part by the Ohio Eminent Scholar Award to M.N. and by grants from the European Community Research and Technological Development program (QLG3-CT-2002-01141), from the French Association pour la Recherche sur le Cancer, France and from institutional funds from the Medical Research Council, UK to F.G.

	REFERENCES

TOP SUMMARY INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

Aguirre, A., Dupree, J. L., Mangin, J. M. and Gallo, V. (2007). A functional role for EGFR signaling in myelination and remyelination. Nat. Neurosci. 10,990 -1002.[CrossRef][Medline]

Barres, B. A. and Raff, M. C. (1994). Control of oligodendrocyte number in the developing rat optic nerve. Neuron 12,935 -942.[CrossRef][Medline]

Battiste, J., Helms, A. W., Kim, E. J., Savage, T. K., Lagace, D. C., Mandyam, C. D., Eisch, A. J., Miyoshi, G. and Johnson, J. E. (2007). Ascl1 defines sequentially generated lineage-restricted neuronal and oligodendrocyte precursor cells in the spinal cord. Development 134,285 -293.[Abstract/Free Full Text]

Cai, J., Qi, Y., Hu, X., Tan, M., Liu, Z., Zhang, J., Li, Q., Sander, M. and Qiu, M. (2005). Generation of oligodendrocyte precursor cells from mouse dorsal spinal cord independent of Nkx6 regulation and Shh signaling. Neuron 45, 41-53.[CrossRef][Medline]

Cai, J., Chen, Y., Cai, W. H., Hurlock, E. C., Wu, H., Kernie, S. G., Parada, L. F. and Lu, Q. R. (2007). A crucial role for Olig2 in white matter astrocyte development. Development 134,1887 -1899.[Abstract/Free Full Text]

Casarosa, S., Fode, C. and Guillemot, F. (1999). Mash1 regulates neurogenesis in the ventral telencephalon. Development 126,525 -534.[Abstract]

Danesin, C., Agius, E., Escalas, N., Ai, X., Emerson, C., Cochard, P. and Soula, C. (2006). Ventral neural progenitors switch toward an oligodendroglial fate in response to increased Sonic hedgehog (Shh) activity: involvement of Sulfatase 1 in modulating Shh signaling in the ventral spinal cord. J. Neurosci. 26,5037 -5048.[Abstract/Free Full Text]

Fogarty, M., Richardson, W. D. and Kessaris, N. (2005). A subset of oligodendrocytes generated from radial glia in the dorsal spinal cord. Development 132,1951 -1959.[Abstract/Free Full Text]

Fu, H., Qi, Y., Tan, M., Cai, J., Takebayashi, H., Nakafuku, M., Richardson, W. and Qiu, M. (2002). Dual origin of spinal oligodendrocyte progenitors and evidence for the cooperative role of Olig2 and Nkx2.2 in the control of oligodendrocyte differentiation. Development 129,681 -693.[Abstract/Free Full Text]

Gokhan, S., Marin-Husstege, M., Yung, S. Y., Fontanez, D., Casaccia-Bonnefil, P. and Mehler, M. F. (2005). Combinatorial profiles of oligodendrocyte-selective classes of transcriptional regulators differentially modulate myelin basic protein gene expression. J. Neurosci. 25,8311 -8321.[Abstract/Free Full Text]

Gong, S., Zheng, C., Doughty, M. L., Losos, K., Didkovsky, N., Schambra, U. B., Nowak, N. J., Joyner, A., Leblanc, G., Hatten, M. E. et al. (2003). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425,917 -925.[CrossRef][Medline]

Helms, A. W., Battiste, J., Henke, R. M., Nakada, Y., Simplicio, N., Guillemot, F. and Johnson, J. E. (2005). Sequential roles for Mash1 and Ngn2 in the generation of dorsal spinal cord interneurons. Development 132,2709 -2719.[Abstract/Free Full Text]

Kessaris, N., Fogarty, M., Iannarelli, P., Grist, M., Wegner, M. and Richardson, W. D. (2006). Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nat. Neurosci. 9, 173-179.[CrossRef][Medline]

Kim, E. J., Leung, C. T., Reed, R. R. and Johnson, J. E. (2007). In vivo analysis of Ascl1 defined progenitors reveals distinct developmental dynamics during adult neurogenesis and gliogenesis. J. Neurosci. 27,12764 -12774.[Abstract/Free Full Text]

Kitada, M. and Rowitch, D. H. (2006). Transcription factor co-expression patterns indicate heterogeneity of oligodendroglial subpopulations in adult spinal cord. Glia 54,35 -46.[CrossRef][Medline]

Kondo, T. and Raff, M. (2000a). Basic helix-loop-helix proteins and the timing of oligodendrocyte differentiation. Development 127,2989 -2998.[Abstract]

Kondo, T. and Raff, M. (2000b). The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J. 19,1998 -2007.[CrossRef][Medline]

Liu, A., Li, J., Marin-Husstege, M., Kageyama, R., Fan, Y., Gelinas, C. and Casaccia-Bonnefil, P. (2006). A molecular insight of Hes5-dependent inhibition of myelin gene expression: old partners and new players. EMBO J. 25,4833 -4842.[CrossRef][Medline]

Liu, R., Cai, J., Hu, X., Tan, M., Qi, Y., German, M., Rubenstein, J., Sander, M. and Qiu, M. (2003). Region-specific and stage-dependent regulation of Olig gene expression and oligodendrogenesis by Nkx6.1 homeodomain transcription factor. Development 130,6221 -6231.[Abstract/Free Full Text]

Liu, Y. and Rao, M. S. (2004). Olig genes are expressed in a heterogeneous population of precursor cells in the developing spinal cord. Glia 45,67 -74.[CrossRef][Medline]

Liu, Z., Hu, X., Cai, J., Liu, B., Peng, X., Wegner, M. and Qiu, M. (2007). Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence for reciprocal interactions and dosage-dependent mechanisms. Dev. Biol. 302,683 -693.[CrossRef][Medline]

Lu, Q. R., Sun, T., Zhu, Z., Ma, N., Garcia, M., Stiles, C. D. and Rowitch, D. H. (2002). Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 109,75 -86.[CrossRef][Medline]

Masahira, N., Takebayashi, H., Ono, K., Watanabe, K., Ding, L., Furusho, M., Ogawa, Y., Nabeshima, Y., Alvarez-Buylla, A., Shimizu, K. et al. (2006). Olig2-positive progenitors in the embryonic spinal cord give rise not only to motoneurons and oligodendrocytes, but also to a subset of astrocytes and ependymal cells. Dev. Biol. 293,358 -369.[CrossRef][Medline]

Mizuguchi, R., Sugimori, M., Takebayashi, H., Kosako, H., Nagao, M., Yoshida, S., Nabeshima, Y., Shimamura, K. and Nakafuku, M. (2001). Combinatorial roles of olig2 and neurogenin2 in the coordinated induction of pan-neuronal and subtype-specific properties of motoneurons. Neuron 31,757 -771.[CrossRef][Medline]

Mizuguchi, R., Kriks, S., Cordes, R., Gossler, A., Ma, Q. and Goulding, M. (2006). Ascl1 and Gsh1/2 control inhibitory and excitatory cell fate in spinal sensory interneurons. Nat. Neurosci. 9,770 -778.[CrossRef][Medline]

Noble, M., Proschel, C. and Mayer-Proschel, M. (2004). Getting a GR(i)P on oligodendrocyte development. Dev. Biol. 265,33 -52.[CrossRef][Medline]

Ohori, Y., Yamamoto, S., Nagao, M., Sugimori, M., Yamamoto, N., Nakamura, K. and Nakafuku, M. (2006). Growth factor treatment and genetic manipulation stimulate neurogenesis and oligodendrogenesis by endogenous neural progenitors in the injured adult spinal cord. J. Neurosci. 26,11948 -11960.[Abstract/Free Full Text]

Parras, C. M., Schuurmans, C., Scardigli, R., Kim, J., Anderson, D. J. and Guillemot, F. (2002). Divergent functions of the proneural genes Mash1 and Ngn2 in the specification of neuronal subtype identity. Genes Dev. 16,324 -338.[Abstract/Free Full Text]

Parras, C. M., Galli, R., Britz, O., Soares, S., Galichet, C., Battiste, J., Johnson, J. E., Nakafuku, M., Vescovi, A. and Guillemot, F. (2004). Mash1 specifies neurons and oligodendrocytes in the postnatal brain. EMBO J. 23,4495 -4505.[CrossRef][Medline]

Parras, C. M., Hunt, C., Sugimori, M., Nakafuku, M., Rowitch, D. and Guillemot, F. (2007). The proneural gene Mash1 specifies an early population of telencephalic oligodendrocytes. J. Neurosci. 27,4233 -4242.[Abstract/Free Full Text]

Petryniak, M. A., Potter, G. B., Rowitch, D. H. and Rubenstein, J. L. R. (2007). Dlx1 and Dlx2 control neuronal versus oligodendroglial cell fate acquisition in the developing forebrain. Neuron 55,417 -433.[CrossRef][Medline]

Qi, Y., Cai, J., Wu, Y., Wu, R., Lee, J., Fu, H., Rao, M., Sussel, L., Rubenstein, J. and Qiu, M. (2001). Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development 128,2723 -2733.[Medline]

Raff, M. C. (1989). Glial cell diversification in the rat optic nerve. Science 243,1450 -1455.[Abstract/Free Full Text]

Richardson, W. D., Kessaris, N. and Pringle, N. (2006). Oligodendrocyte wars. Nat. Rev. Neurosci. 7,11 -18.[CrossRef][Medline]

Rowitch, D. H. (2004). Glial specification in the vertebrate neural tube. Nat. Rev. Neurosci. 5, 409-419.[Medline]

Samanta, J. and Kessler, J. A. (2004). Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation. Development 131,4131 -4142.[Abstract/Free Full Text]

Sohn, J., Natale, J., Chew, L. J., Belachew, S., Cheng, Y., Aguirre, A., Lytle, J., Nait-Oumesmar, B., Kerninon, C., Kanai-Azuma, M. et al. (2006). Identification of Sox17 as a transcription factor that regulates oligodendrocyte development. J. Neurosci. 26,9722 -9735.[Abstract/Free Full Text]

Spassky, N., Goujet-Zalc, C., Parmantier, E., Olivier, C., Martinez, S., Ivanova, A., Ikenaka, K., Macklin, W., Cerruti, I., Zalc, B. et al. (1998). Multiple restricted origin of oligodendrocytes. J. Neurosci. 18,8331 -8343.[Abstract/Free Full Text]

Stolt, C. C., Rehberg, S., Ader, M., Lommes, P., Riethmacher, D., Schachner, M., Bartsch, U. and Wegner, M. (2002). Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10. Genes Dev. 16,165 -170.[Abstract/Free Full Text]

Stolt, C. C., Lommes, P., Sock, E., Chaboissier, M. C., Schedl, A. and Wegner, M. (2003). The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes Dev. 17,1677 -1689.[Abstract/Free Full Text]

Stolt, C. C., Lommes, P., Friedrich, R. P. and Wegner, M. (2004). Transcription factors Sox8 and Sox10 perform non-equivalent roles during oligodendrocyte development despite functional redundancy. Development 131,2349 -2358.[Abstract/Free Full Text]

Stolt, C. C., Schlierf, A., Lommes, P., Hillgartner, S., Werner, T., Kosian, T., Sock, E., Kessaris, N., Richardson, W. D., Lefebvre, V. et al. (2006). SoxD proteins influence multiple stages of oligodendrocyte development and modulate SoxE protein function. Dev. Cell 11,697 -709.[CrossRef][Medline]

Sugimori, M., Nagao, M., Bertrand, N., Parras, C. M., Guillemot, F. and Nakafuku, M. (2007). Combinatorial actions of patterning and HLH transcription factors in the spatiotemporal control of neurogenesis and gliogenesis in the developing spinal cord. Development 134,1617 -1629.[Abstract/Free Full Text]

Sun, T., Echelard, Y., Lu, R., Yuk, D. I., Kaing, S., Stiles, C. D. and Rowitch, D. H. (2001). Olig bHLH proteins interact with homeodomain proteins to regulate cell fate acquisition in progenitors of the ventral neural tube. Curr. Biol. 11,1413 -1420.[CrossRef][Medline]

Takebayashi, H., Nabeshima, Y., Yoshida, S., Chisaka, O., Ikenaka, K. and Nabeshima, Y. (2002). The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages. Curr. Biol. 12,1157 -1163.[Cr